HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia. The company also holds the U.S. marketing rights of Absorica, a commercial stage dermatology product. HLS Therapeutics Inc. has a license agreement with Amarin Corporation plc to register, commercialize, and distribute Vascepa capsules in Canada. The company was founded in 2018 and is headquartered in Toronto, Canada.